Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167

Benzinga · 17h ago
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.